Novel Immunotherapies for Myasthenia Gravis
Abstract
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies. Advances in the immunology and pathogenesis of MG have ushered in an era of newer therapies which are more specific and efficacious. Complement inhibitors and neonatal Fc receptor blockers target disease-specific pathogenic mechanisms linked to myasthenia and have proven their efficacy in pivotal clinical studies. B cell-depleting agents, specifically rituximab, have also emerged as useful for the treatment of severe MG. Many more biologicals are in the pipeline and in diverse stages of development. This review discusses the evidence for the novel therapies and the specific issues related to their clinical use.
Related
- Individualized sequencing of targeted immunotherapies in generalized myasthenia gravis across distinct patient profiles
- Commentary: Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case
- Anesthetic Management of a Patient With Myasthenia Gravis Undergoing Thoracoscopic Thymectomy: A Case Report and Literature Review
- Perioperative local anesthetic and antibiotic considerations during Mohs micrographic surgery on a patient with myasthenia gravis
BibTeX
@article{nair2026novel,
title = {{Novel Immunotherapies for Myasthenia Gravis}},
author = {Sruthi Nair and Saiju Jacob},
journal = {ImmunoTargets and Therapy},
year = {2026},
month = oct,
doi = {10.2147/itt.s377056},
url = {https://hal.science/hal-05784834v1},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Novel Immunotherapies for Myasthenia Gravis
AU - Sruthi Nair
AU - Saiju Jacob
PY - 2026
DA - 2026/10/07
JO - ImmunoTargets and Therapy
DO - 10.2147/itt.s377056
UR - https://hal.science/hal-05784834v1
AB - Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies. Advances in the immunology and pathogenesis of MG have ushered in an era of newer therapies which are more specific and efficacious. Complement inhibitors and neonatal Fc receptor blockers target disease-specific pathogenic mechanisms linked to myasthenia and have proven their efficacy in pivotal clinical studies. B cell-depleting agents, specifically rituximab, have also emerged as useful for the treatment of severe MG. Many more biologicals are in the pipeline and in diverse stages of development. This review discusses the evidence for the novel therapies and the specific issues related to their clinical use.
SN - 2253-1556
ER -